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ABSTRACT
Background: Perioperative hypothermia has been reported
to increase the occurrence of cardiovascular complications.
By increasing the activity of sympathetic nervous system,
perioperative hypothermia also has the potential to in-
crease cardiac injury and dysfunction associated with sub-
arachnoid hemorrhage.
Methods: The Intraoperative Hypothermia for Aneurysm
Surgery Trial randomized patients undergoing cerebral an-
eurysm surgery to intraoperative hypothermia (n  499,
33.3° 0.8°C) or normothermia (n 501, 36.7° 0.5°C).
Cardiovascular events (hypotension, arrhythmias, vasopres-
sor use,myocardial infarction, and others) were prospectively
followed until 3-month follow-up and were compared in
hypothermic and normothermic patients. A subset of 62 pa-
tients (hypothermia, n  33; normothermia, n  29) also
had preoperative and postoperative (within 24 h) measure-
ment of cardiac troponin-I and echocardiography to explore
the association between perioperative hypothermia and sub-
arachnoid hemorrhage-associated myocardial injury and left
ventricular function.
Results: There was no difference between hypothermic
and normothermic patients in the occurrence of any single
cardiovascular event or in composite cardiovascular
events. There was no difference in mortality (6%) between
groups, and there was only a single primary cardiovascular
death (normothermia). There was no difference between hypo-
thermic and normothermic patients in postoperative versus pre-
operative left ventricular regional wall motion or ejection frac-
tion. Comparedwith preoperative values, hypothermic patients
had no postoperative increase in cardiac troponin-I (median
change 0.00 g/l), whereas normothermic patients had a small
postoperative increase (median change  0.01 g/l, P 
0.038).
Conclusion: In patients undergoing cerebral aneurysm sur-
gery, perioperative hypothermia was not associated with an
increased occurrence of cardiovascular events.
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THERE is a continued interest in the potential benefitof mild systemic hypothermia in the treatment of
various neurologic insults such as stroke, head trauma,
and anoxic-ischemic brain injury after cardiac arrest.1
Counterbalancing potential neurologic benefits of hypo-
thermia are several known or potential risks. For example,
in the perioperative period, mild systemic hypothermia
has been reported to increase the occurrence of various
cardiovascular events 2- to 6-fold.2–4 The Intraoperative
Hypothermia for Aneurysm Surgery Trial (IHAST) was a
multicenter, prospective, randomized, partially blinded
trial designed to determine whether mild intraoperative
systemic hypothermia (33°C) would improve neurologic
outcome in patients undergoing surgery to treat acutely
ruptured intracranial aneurysms when compared with in-
traoperative normothermia.5 As a part of trial safety mon-
itoring, IHAST prospectively followed events in other or-
gan systems, including the cardiovascular system. The aim
of the current study was to test the hypothesis that intra-
operative hypothermia was associated with a greater oc-
currence of cardiovascular events.
Some patients with subarachnoid hemorrhage (SAH)
have signs of SAH-associated myocardial injury and dys-
function, such as positive myocardial enzymes, regional
wall motion abnormalities, and left ventricular (LV) dys-
function.6 These abnormalities seem to be mediated by
excessive catecholamine activity, both systemically and at
cardiac sympathetic nerve terminals.7,8 Because perioper-
ative hypothermia increases postoperative catecholamine
levels,9 perioperative hypothermia may worsen SAH-asso-
ciated cardiac abnormalities. To explore whether periop-
erative hypothermia increased SAH-associated cardiac
abnormalities, a subset of IHAST patients underwent pre-
operative and postoperative assessments of myoca-
rdial injury (cardiac troponin-I [cTnI]) and LV function
(echocardiography).
Materials and Methods
The details of IHAST design, patient eligibility, proto-
cols, and outcome assessment have been published previ-
ously.5 In brief, between February 2000 and April 2003,
nonpregnant adults with SAH and an angiographically
confirmed intracranial aneurysm scheduled to undergo
surgical treatment within 14 days of hemorrhage were
eligible to participate. Other major inclusion criteria in-
cluded a preoperative World Federation of Neurologic
Surgeons (WFNS) class of I, II, or III10 and not being
tracheally intubated at the time of study enrollment.
IHAST protocols were approved by the Human Subjects
Committees at each participating center (n  30), and
written informed consent was obtained from either pa-
tients or their families.
Anesthesia and Temperature Management
Anesthesia was induced with thiopental or etomidate and
maintained with isoflurane or desflurane, fentanyl or
remifentanil, and nitrous oxide or air with oxygen. Selec-
tion of intraoperative monitoring was determined by the
preferences of each operating team, although all patients
had intraarterial blood pressure monitoring. After induc-
tion of general anesthesia, patients were randomized to
one of two groups: (1) hypothermia (target esophageal
temperature, 33.0°C) or (2) normothermia (target esoph-
ageal temperature, 36.5°C), which were achieved with
surface techniques. Knowledge of intraoperative temper-
ature was limited to each patient’s anesthesiologist; sur-
geons were not informed of patient temperature. Intraop-
erative heart rate and systemic blood pressure, and
methods used to achieve desired levels for these variables
(e.g., vasoactive agents or fluids), were determined by each
patient’s anesthesiologist and operative team. Other med-
ications, such as neuromuscular blockers, antiemetics, and
analgesics, were determined similarly. Rewarming of hy-
pothermic patients began after the last aneurysm had been
secured. Based on a pilot study,11 it was anticipated that
many patients assigned to hypothermia would not be
completely rewarmed by the end of the surgery. IHAST
protocols recommended that patients who were still hy-
pothermic (below 35.5°C) at the end of the surgery should
remain intubated and sedated with propofol12 until nor-
mothermia was restored. In all patients, the goal was to
return the patient to a state in which neurologic assess-
ment and extubation were possible after the end of
surgery.
IHAST Data Collection and Safety Monitoring
All IHAST data collection, preoperative and postopera-
tive management decisions, and outcome assessments
were made by persons who had no knowledge of temper-
ature group assignment. Preoperative data collection in-
cluded patient demographics and pre-SAH medical his-
tory. Information regarding the characteristics of the
ruptured aneurysm (location and angiographic diameter)
and its immediate effects (amount of subarachnoid blood
[Fisher Scale],13 WFNS class,10 and National Institutes of
Health Stroke Scale14) were recorded before the surgery.
Postoperative management was not standardized, but all
What We Already Know about This Topic
❖ Perioperative hypothermia has been associated with postop-
erative cardiovascular complications, including cardiac injury
and dysfunction
What This Article Tells Us That Is New
❖ In 1,000 patients randomized to normothermia or mild (33°C)
hypothermia during craniotomy, patients were rewarmed be-
fore endotracheal extubation, even if this required ventilation
in the postanesthesia recovery area for 2 hr
❖ Under these circumstances, intraoperative and very early
postoperative hypothermia was not associated with an in-
crease in adverse cardiovascular events
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aspects of treatment and patient condition were prospec-
tively documented daily from enrollment to postoperative
day 14 or discharge, whichever came first. A final outcome
assessment was conducted approximately 3 months after
surgery.
At every patient encounter, patients were assessed for the
occurrence of any of 106 predefined events or procedures,
collectively referred to as intercurrent events (IEs). IEs were
categorized as occurring in one of nine body systems: (1)
whole body or general, (2) cardiovascular, (3) respiratory, (4)
digestive, (5) endocrine or metabolic, (6) neurologic or neu-
rosurgical, (7) urogenital, (8) coagulation or hematologic,
and (9) other or unclassified. Across all nine IE categories, a
total of 68 specific events and 38 procedures or interventions
were followed. Each IE had predefined diagnostic criteria
based on published guidelines, standards, or consensus state-
ments available at the start of the trial. Each IE was classified
by local investigators as having its onset during one of five
intervals: (1) preoperative (prerandomization), (2) intraop-
erative, (3) within the first 2 h after surgery, (4) postopera-
tively (from 2 h after surgery until 14 days or discharge), or
(5) from discharge to final 3-month follow-up.
The severity and clinical impact of each IE were clas-
sified by local investigators as (1) mild, (2) moderate, (3)
severe, or (4) fatal. Mild events were defined as being well
tolerated and not appearing to substantially influence the
patient’s overall clinical course. Moderate events were suf-
ficient to interfere with the patient’s recovery; usually
some new treatment was necessary, and the duration of
hospitalization was slightly prolonged. Severe events were
life threatening, permanently disabling, or substantively
prolonged in-patient hospitalization. IEs with a rating of
death were those that resulted in patient death.
A predefined subset of IEs (n 27) were designated as
“indicator” IEs. Indicator IEs were events that previous
studies had suggested might occur more often in patients
with intraoperative hypothermia, such as major cardiovas-
cular events,2–4 infection,15 or bleeding,16 and events as-
sociated with major neurologic morbidity (e.g., intracra-
nial hemorrhage, intracranial hypertension, brain
swelling, and cerebral infarction). The occurrence of any
indicator IE, regardless of severity, or any IE classified by
local investigators as severe or associated with a patient
death, required a report to the IHAST Clinical Coordi-
nating Center (CCC) within 1 work day.
The IHAST CCC monitored all IE reports. All CCC
personnel were blinded to each patient’s temperature as-
signment and all intraoperative temperature data. All IE
reports were reviewed by a CCC physician (B.H.) who
verified that diagnostic criteria were met and that all as-
sociated IEs were coded and documented in accordance
with IHAST procedures. The CCC communicated with
local investigators to resolve all apparent discrepancies
and reporting errors. The CCC maintained a real-time
database of all IE reports. This database was monitored by
the Data Management Center and was freely available to
the trial’s Physician Safety Monitor who was authorized to
stop the trial at any time if any disproportionate or unex-
pected risk was suspected.
Any patient death required the local investigator to
provide a supplemental report describing the circum-
stances and causes of the patient’s death. For each patient
who died, a CCC physician (B.H.) reviewed all IHAST
case report forms and collected all available supplemental
supporting documents (e.g., autopsy reports) to prepare a
detailed clinical summary. The only information that was
excluded from this review was patient intraoperative tem-
perature. Based on this review, primary and secondary
causes of death and corresponding International Cla-
ssification of Disease-10 codes were assigned. The clinical
summaries were immediately provided to the IHAST
Principal Investigator (M.T.) and Physician Safety
Monitor.
Cardiovascular Events
Diagnostic criteria for 26 IHAST cardiovascular IEs are
summarized in appendix 2. Eight of the 26 cardiovascular
events (e.g., myocardial infarction, ventricular arrhyth-
mias, and vasopressors to support the systemic circula-
tion) were also designated as indicator IEs. Because both
hypotension and hypertension can be deliberately used in
the treatment of cerebral aneurysm patients, these two
events were classified as either intended or not intended.
Vasopressor use was classified as for cardiovascular indi-
cations (e.g., hypotension, low cardiac output), neurologic
indications (e.g., to support cerebral perfusion), or for
other indications.
For cardiovascular events occurring in 20% of normo-
thermic patients, IHAST had sufficient statistical power
( 0.05,  0.20) to detect an absolute increase of 8%
(relative increase 28/20%  1.40) in hypothermic pa-
tients. For cardiovascular events occurring in 10 and 5%
of normothermic patients, IHAST had sufficient statisti-
cal power to detect absolute increases of 6.5 and 5% and
relative increases of 1.65 and 2.00 in hypothermic pa-
tients, respectively.
Myocardial Injury and Dysfunction Sub-study
With the approval of the IHAST Data and Safety Monitor-
ing Board, in December 2000, 12 IHAST centers were in-
vited to participate in a supplementary exploratory study, the
Myocardial Injury and Dysfunction Sub-Study (MIDS).
Seven centers accepted (appendix 1), and in these centers,
informed consent documents included additional informa-
tion regarding MIDS procedures. The aim of MIDS was to
determine whether perioperative hypothermia was associated
with increases in troponin release, LV dysfunction, or re-
gional wall motion abnormalities.
Patients enrolled in MIDS (n 62) underwent preop-
erative and postoperative blood collection and transtho-
racic echocardiography (TTE). Preoperative TTE and se-
rum collection were obtained not more than 24 h before
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surgery, and both procedures were repeated within 8–24
h after surgery. TTE system settings were chosen to max-
imize the resolution of LV endocardial borders, using har-
monic imaging when available. During both TTE studies,
the following echocardiographic views were acquired:
parasternal long axis, parasternal short axis (midpapillary
level), apical four-chamber, apical two-chamber, and api-
cal three-chamber. No identifying information was in-
cluded with the TTE images other than the IHAST pa-
tient identification number.
Each echocardiogram was sent to the IHAST CCC and
assigned a code number to blind the core echo laboratory
to patient randomization status, the timing of the exami-
nation relative to surgery, and all other clinical informa-
tion. All coded TEE studies were interpreted by a single
experienced echocardiographer (J.Z.). LV ejection frac-
tion (LVEF) was measured using standard methodolo-
gy.17 Regional LV function was defined using a 16-seg-
ment wall motion score in which each segment was graded
as 1 (normal), 2 (hypokinetic), or 3 (akinetic or dyskinet-
ic).17 From these 16 individual scores, a mean regional
wall motion score (RWMS) was calculated. Final TTE
results were sent to the IHAST CCC, decoded, and in-
cluded in the database.
In MIDS patients, 10 ml of blood was obtained preop-
eratively and postoperatively using serum separator tubes.
After standing upright for 30 min, each tube was centri-
fuged for 5 min, and the serum was placed into a polypro-
pylene tube and stored at 70°C. Each tube was labeled
with a code number and no patient identifiers. At the
conclusion of the study, all samples were shipped on dry
ice to the University of Western Ontario, thawed, and
serum levels of cTnI were measured (Beckman Coulter
Access 2, Chemiluminescence Immunoassay; Beckman
Coulter Canada Inc., Mississauga, ON, Canada). The
lower limit of detection of this assay was 0.03 g/l, and
this value was assigned to all patients when no activity was
detected. Final cTnI results were sent to the IHAST CCC,
decoded, and included in the database.
MIDS prestudy power analysis was based on data indi-
cating that 25% of patients with SAH would have at least
some preoperative wall motion abnormalities (RWMS 
1.0 with SD of 0.3).6 We assumed that only those patients
with preoperative RWMS more than 1.0 would be at sig-
nificant risk to develop new or worsened wall motion and
that hypothermia would increase risk relative to normo-
thermia. To detect a between-group difference of 0.4
units in mean RWMS (  0.05,   0.20) would re-
quire 11 patients per group or a total of 22 patients with
preoperative wall motion abnormalities. Therefore, the
necessary MIDS sample size was estimated to be (22  4)
88 patients.
Statistical Methods
All data entry was performed by the Data Management Center
at theUniversity of Iowa. Statistical analyses were performed on
SAS version 9.1.3 Service Pack XP_PRO Platform (SAS Insti-
tute Inc., Cary, NC). Power analyses were performed using
nQuery Advisor version 7.0 (Statistical Solutions Ltd., Cork,
Ireland). All analyses were based on intention to treat. The uni-
variate tests used included the Fisher exact test and Wilcoxon
rank sum test depending on the characteristics and distribution
of the data. In all analyses, all P values are two-sided with P
0.05 as the threshold for a statistically significant difference or
association without adjustment for multiple comparisons.
For the entire IHAST population (n  1,000), preop-
erative and postoperative variables and the occurrence of
cardiovascular events were compared in hypothermic and
normothermic patients. For this analysis, cardiovascular
events were classified as having their onset in one of two
periods: (1) perioperative events with their onset intraop-
eratively or during the first 2 h after surgery or (2) post-
operative events with their onset more than 2 h after sur-
gery until the 3-month outcome assessment. For
individual event analysis, cardiovascular events were clas-
sified as either present (any severity) or absent. To increase
statistical power to detect the differences between temper-
ature groups, cardiovascular events were grouped post hoc
into various composite categories (e.g., any cardiovascular
event, any indicator event). For the calculation of com-
posite cardiovascular events, 4 of the 26 cardiovascular IEs
were excluded. Hypertension and hypotension that were
intended were excluded. Electrocardiography and echo-
cardiography were also excluded because they are proce-
dures and do not necessarily indicate that a cardiovascular
event occurred. For all composite events, odds ratios and
95% CI were also calculated, using normothermia as the
reference group.
For the MIDS population (n  62), preoperative and
postoperative values for cTnI, RWMS, and LVEFwere com-
pared in hypothermic and normothermic patients. In addi-
tion, using paired preoperative and postoperative values, the
change in each of these variables was calculated and com-
pared in hypothermic and normothermic patients. Because
there is no established threshold for a clinically significant
cTnI value in the setting of SAH, absolute cTnI values were
compared.
Results
Entire IHAST Population
The characteristics of the entire IHAST population (n 
1,000) are summarized in table 1. With one exception, pa-
tients randomized to hypothermia (n  499) and normo-
thermia (n  501) were equivalent in terms of age, sex,
pre-SAH cardiovascular history, preoperative neurologic
condition, severity of SAH, and cerebral aneurysm charac-
teristics. A history of pre-SAH coronary artery disease (CAD)
was slightly more common in patients randomized to hypo-
thermia than those randomized to normothermia, 7 versus
4%, respectively, P  0.017.
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Temperature on arrival to the operating room did not
differ between patients randomized to hypothermia and nor-
mothermia. Patients randomized to intraoperative hypother-
mia had a core temperature of 33.3° 0.8°C at the time of
first aneurysm clipping. Although rewarming of hypother-
mic patients began after final clip placement, core tempera-
tures increased by only approximately 1°C by the end of the
surgery (34.2°  0.9°C). Consequently, 60% of those ran-
domized to hypothermia remained intubated on arrival to
the postoperative care area compared with 24% of those
assigned to normothermia, P 0.001. Continued postoper-
ative rewarming resulted in core temperatures that were
nearly normal by 2 h after surgery. However, at 2 h after
surgery, patients randomized to hypothermia continued to
be intubated more often than patients randomized to nor-
mothermia, 25 versus 13%, respectively, P 0.001. At 24 h
after surgery, intubation was equally common in both groups
(i.e., approximately 10%).
As summarized in tables 2 and 3, during the perioperative
period (during surgery and the first 2 h after surgery), the
most common cardiovascular events were vasopressor ad-
ministration (25% of patients) and unintended hypertension
(7% of patients). During this period, arrhythmias and unin-
tended hypotension were each reported in less than 5% of
patients. In the postoperative period, the most common car-
diovascular events were vasopressor administration (22%),
congestive heart failure or pulmonary edema (9%), and un-
intended hypertension (9%). Nonventricular arrhythmias
(6%), unintended hypotension (4%), andmyocardial infarc-
tion and ventricular arrhythmias (1%) were infrequent post-
operative cardiovascular events.
As shown in table 2, there were no differences between
hypothermic and normothermic patients in the occurrence
of any single cardiovascular event during either the perioper-
ative or the postoperative period. Likewise, as summarized in
table 3, the number of patients who experienced any cardio-
Table 1. Patient Characteristics, Temperatures, and Intubation Status
Characteristic
Temperature Group
P ValueHypothermia (n  499) Normothermia (n  501)
Age, yr 52  12 51  13 0.22
Female 325 (65) 330 (66) 0.84
Current or former smoker 309 (62) 332 (66) 0.17
History of hypertension 199 (40) 199 (40) 1.00
History of coronary artery disease 35 (7) 18 (4) 0.017
History of ventricular dysfunction 2 ( 1) 3 (1) 1.00
History of valvular dysfunction 5 (1) 4 (1) 0.75
History of dysrhythmia 13 (3) 10 (2) 0.54
Preoperative WFNS score 0.81
I 332 (67) 328 (66)
II 140 (28) 149 (30)
III 27 (5) 24 (5)
Preoperative Fisher score 0.81
1 30 (6) 24 (5)
2 172 (35) 170 (34)
3 235 (47) 239 (48)
4 62 (12) 68 (14)
Aneurysm size, mm* 0.07
1–11 403 (81) 401 (80)
12–24 85 (17) 79 (16)
25 8 (2) 20 (4)
Aneurysm location† 0.91
Anterior 458 (92) 457 (91)
Posterior 41 (8) 43 (9)
Temperature on arrival to operating room, °C 36.8  0.7 36.8  0.6 0.91
Temperature at first aneurysm clip, °C 33.3  0.8 36.7  0.5  0.001
Temperature at end of surgery, °C 34.2  0.9 36.8  0.6  0.001
Intubated at end of surgery 297 (60) 122 (24)  0.001
Temperature 2 h after surgery, °C 36.4  1.0 37.1  0.7  0.001
Intubated 2 h after surgery 125 (25) 66 (13)  0.001
Intubated 24 h after surgery 48 (10) 51 (10) 0.83
Data are expressed as mean  SD or n (%).
* Four patients with missing data for aneurysm size; hypothermia (n  3) and normothermia (n  1). † One normothermic patient with
missing data for aneurysm location. Anterior aneurysms were defined as those involving the carotid, ophthalmic, anterior choroidal,
middle cerebral, anterior communicating, posterior communicating, and anterior cerebral arteries. Posterior aneurysms included those
involving the vertebrobasilar and posterior inferior cerebellar arteries.
WFNS  World Federation of Neurological Surgeons.
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vascular event, received any vasopressor, experienced any
“indicator” cardiovascular event, any cardiac morbidity
(myocardial infarction, pulmonary edema, ventricular ar-
rhythmias, or cardioversion/defibrillation), or death did not
differ in hypothermic and normothermic patients.
Sixty-one patients died between randomization and
3-month follow-up. The primary causes of death were neu-
rologic in 46 patients (75%), respiratory in 6 (10%), pulmo-
nary embolus in 4 (7%), sepsis in 4 (7%), and cardiovascular
in 1 patient (less than 2%). In the latter patient, deliberate
intraoperative hypotensionwas used to reduce aneurysmwall
tension under normothermic conditions. The patient acutely
developed ventricular fibrillation, and resuscitation was un-
successful. An autopsy revealed previously unrecognized se-
vere three-vessel atherosclerotic CAD. The presumptive
mechanism of death was hypotension-induced myocardial
Table 2. Cardiovascular Events or Procedures
Event or Procedure Period*
Temperature Group
P
Value
Hypothermia
(n  499)
Normothermia
(n  501)
Hypertension, not intended Perioperative 32 (6) 33 (7) 1.00
Postoperative 47 (9) 41 (8) 0.51
Hypertension, intended Perioperative 14 (3) 11 (2) 0.55
Postoperative 24 (5) 23 (5) 0.88
Hypotension, not intended Perioperative 19 (4) 18 (4) 0.87
Postoperative 18 (4) 14 (4) 0.48
Hypotension, intended Perioperative 20 (4) 26 (5) 0.45
Postoperative 1 ( 1) 0 (0) 1.00†
Vasopressor, systemic‡ Perioperative 44 (9) 41 (8) 0.74
Postoperative 24 (5) 16 (3) 0.20
Vasopressor, cerebral Perioperative 101 (20) 91 (18) 0.42
Postoperative 95 (19) 89 (18) 0.63
Vasopressor, other Perioperative 0 (0) 0 (0) 1.00†
Postoperative 1 ( 1) 2 ( 1) 1.00
Myocardial ischemia or infarction‡ Perioperative 0 (0) 1 ( 1)§ 1.00
Postoperative 9 (2) 4 (1) 0.18
Congestive heart failure or pulmonary edema Perioperative 10 (2) 13 (3) 0.67
Postoperative 44 (9) 50 (10) 0.59
Cardiogenic shock‡ Perioperative 0 (0) 1 ( 1)§ 1.00
Postoperative 0 (0) 0 (0) 1.00
Nonventricular arrhythmia Perioperative 25 (5) 23 (5) 0.77
Postoperative 27 (5) 34 (7) 0.43
Ventricular fibrillation or ventricular tachycardia‡ Perioperative 0 (0) 1 ( 1)§ 1.00
Postoperative 6 (1) 2 ( 1) 0.18
Other significant cardiovascular disorder or complication Perioperative 0 (0) 0 (0) 1.00†
Postoperative 8 (2) 13 (3) 0.38
Cardioversion or defibrillation Perioperative 0 (0) 2 ( 1)§ 0.50
Postoperative 2 ( 1) 3 ( 1) 1.00
Cardiac pacemaker placement Perioperative 0 (0) 1 ( 1) 1.00
Postoperative 0 (0) 1 ( 1) 1.00
Cardiopulmonary resuscitation‡ Perioperative 1 ( 1)# 1 ( 1)§ 1.00†
Postoperative 7 (1) 2 ( 1) 0.11
Coronary angiogram‡ Perioperative 0 (0) 0 (0) 1.00†
Postoperative 1 ( 1) 1 ( 1) 1.00
Coronary angioplasty and stenting‡ Perioperative 0 (0) 0 (0) 1.00†
Postoperative 1 ( 1) 0 (0) 0.50
Cardiac surgery‡ Perioperative 0 (0) 0 (0) 1.00†
Postoperative 0 (0) 0 (0) 1.00†
Vascular surgery Perioperative 0 (0) 0 (0) 1.00†
Postoperative 0 (0) 2 ( 1) 0.50
Other cardiovascular procedure, intervention, or surgery Perioperative 1 ( 1) 0 (0) 0.50
Postoperative 36 (7) 34 (7) 0.81
Data are expressed as n (%). All P values calculated using Fisher exact test.
* Perioperative events had their onset during surgery or during the first 2 h after surgery. Postoperative events had their onset  2 h
after surgery until final 3-month follow-up. † Default P value of 1.00 assigned because the occurrence of event or procedure is too low
to satisfy assumptions of Fisher exact test. ‡ “Indicator” event, see Materials and Methods for definition. § In the perioperative period,
one patient had intraoperative cardiac arrest and death, see Results for details.  All arrhythmias that were not ventricular tachycardia
or ventricular fibrillation, including sinus bradycardia. # In the perioperative period, one patient had transient bradycardia or asystole in
postoperative care area that responded to pharmacologic treatment.
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ischemia and arrhythmia. Fourteen patients (hypothermia,
n  8; normothermia, n  6) had 30 postoperative cardio-
vascular IEs rated by local investigators as fatal. However,
none of these cardiovascular events was a direct or primary
cause of death. Two patients with severe postoperative neu-
rologic injury experienced cardiac arrest of unknown cause.
One patient with severe postoperative neurologic injury
and herniation experienced hypotension that was consid-
ered to contribute to death. Finally, one patient with sys-
temic sepsis had bradycardia that was considered to exac-
erbate multisystem failure. One patient died from sepsis
shortly after 3-month follow-up, for a total of 62 deaths in
the trial.
MIDS Population
The preoperative and intraoperative characteristics of MIDS
patients (n 62) did not differ from the rest of the IHAST
population (n  938), with the sole exception that periop-
erative vasopressor use was more common in MIDS patients
than non-MIDS patients, 60 versus 23%, respectively, P 
0.001. The occurrence of cardiovascular events in MIDS
patients did not significantly differ from the rest of the
IHAST population (data available but not shown). Patient
and aneurysm characteristics did not differ inMIDS patients
assigned to hypothermia (n  33) and normothermia (n 
29), and the occurrence of cardiovascular events did not dif-
fer in MIDS patients assigned to hypothermia and normo-
thermia (data available but not shown).
As summarized in table 4, there were no significant dif-
ferences between hypothermic and normothermicMIDS pa-
tients in preoperative LVEF, RWMS, or cTnI. When calcu-
lated as absolute values, values for hypothermic MIDS
patients exhibited no net change in cTnI in preoperative and
postoperative samples (median change 0.00 g/l), whereas,
in normothermic MIDS patients, there was a tiny increase
(median 0.01 g/l). The difference in cTnI change between
temperature groups achieved statistical significance, P 
0.038.
Discussion
Primary Findings
With 1,000 patients, IHAST is the largest study of intraop-
erative hypothermia yet conducted. Cerebral aneurysm sur-
gery patients were randomized tomild systemic hypothermia
(33°C) or normothermia, and the outcomes were prospec-
tively assessed by the examiners unaware of intraoperative
temperature using predefined diagnostic criteria. Periopera-
tive hypothermia was not associated with an improved neu-
rologic outcome 3 months after surgery.5 The key finding of
the current study is that perioperative hypothermia was not
associated with an increase in the occurrence of cardiovascu-
lar events.
Intraoperatively and for the first 2 h after surgery (periop-
erative), hypothermic patients had no greater incidence of
arrhythmias or hypotension and no greater need for vaso-
pressors than patients who were normothermic. This is con-
Table 3. Composite Cardiovascular Events and Mortality
Event or Procedure Period*
Temperature Group
P
Value
Odds Ratio
(95% CI)
Hypothermia
(n  499)
Normothermia
(n  501)
Any cardiovascular event Perioperative 188 (38) 164 (33) 0.11 1.24 (0.96–1.61)
Postoperative 196 (39) 208 (42) 0.48 0.91 (0.71–1.17)
Any vasopressor
administration
Perioperative 132 (26) 118 (24) 0.31 1.17 (0.88–1.55)
Postoperative 116 (23) 105 (21) 0.40 1.14 (0.85–1.54)
Any “indicator”
cardiovascular event
Perioperative 44 (9) 42 (8) 0.82 1.06 (0.68–1.64)
Postoperative 31 (6) 23 (5) 0.27 1.38 (0.79–2.30)
Any cardiovascular event Perioperative† 8 (2) 6 (1) 0.60 1.34 (0.46–3.90)
Rated severe or fatal Postoperative‡ 24 (5) 37 (7) 0.11 0.64 (0.37–1.08)
Myocardial infarction,
congestive heart
failure or pulmonary
edema, ventricular
arrhythmia, and
cardioversion or
defibrillation
Either perioperative
or postoperative
62 (12) 64 (13) 0.92 0.97 (0.67–1.41)
Mortality (any cause) Either perioperative
or postoperative‡
29 (6) 32 (6) 0.79 0.90 (0.54–1.52)
Data are expressed as n (%). All P values calculated using Fisher exact test. All odds ratios calculated with normothermia as the
reference group.
* Perioperative events had their onset during surgery or during the first 2 h after surgery. Postoperative events had their onset more than
2 h after surgery until final 3-month follow-up. † In the perioperative period, one patient had intraoperative cardiac arrest and death, see
Results for details. In the perioperative period, the most common events rated as severe (but nonfatal) were vasopressor, systemic (n
7), hypertension, not intended (n  4), and vasopressor, cerebral (n  2). ‡ See Results regarding postoperative deaths.
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sistent with studies showing that in anesthetized patients,
systemic hemodynamics (e.g., mean arterial pressure, sys-
temic vascular resistance, and heart rate18) and LV perfor-
mance (e.g., cardiac index,18 fractional shortening, and
stroke volume index19) are maintained near normothermic
values during mild systemic hypothermia (32.0°–33.5°C).
Likewise, other than sinus bradycardia, hypothermia-related
arrhythmias are not commonly observed at core tempera-
tures greater than 32°C.20–25
In the perioperative period, 250 patients (25%) received a
vasopressor to support the cerebral circulation (20%)
and/or systemic circulation (9%). This frequency of vaso-
pressor administration is nearly identical to that reported by
Lai et al.26 in a series of 100 patients undergoing cerebral
aneurysm surgery (29%). In IHAST, in only 9 of 250 pa-
tients (4%) was perioperative vasopressor administration
considered by the anesthesiologist to be a severe event. Using
propensity analysis, Fellahi et al.27 reported that in patients
undergoing cardiac surgery, perioperative vasopressor use (pri-
marily dobutamine) was associated with less favorable outcome
(ventricular arrhythmias, myocardial infarction, and death).
This was not the case in the IHAST population. There was no
association between perioperative vasopressor administration
and either postoperative ventricular arrhythmias (P 1.00) or
postoperative myocardial infarction (P 1.00). Similarly, in a
multivariate model that included 10 standard covariates (e.g.,
age, preoperative WFNS class, aneurysm location, and Fisher
score),28 there was no significant association between perioper-
ative vasopressor administration and mortality (P 0.09; data
available but not shown).
There was one cardiovascular death in the perioperative
period, but this was not related to hypothermia. Rather,
death seemed to be related to the use of deliberate (intended)
hypotension in a normothermic patient with unrecognized
three-vessel CAD. Although previously a common practice,
induced hypotension is now infrequently used in cerebral
aneurysm surgery. In IHAST, deliberate intraoperative hy-
potension was used in 16 of 30 centers and in less than 5% of
patients. In a multivariate model that included 10 standard
covariates (e.g., age, preoperative WFNS class, aneurysm lo-
cation, Fisher score),28 there was no significant association
between perioperative intended hypotension and mortality
(P  0.90; data available but not shown).
In the postoperative period, vasopressor administration
remained the most frequent cardiovascular event (20% of
patients), given primarily to support the cerebral circulation.
Postoperative congestive heart failure or pulmonary edema
occurred in approximately 9% of patients. These two events
are most likely the linked consequence of hypertensive hy-
pervolemic hemodilution (“triple H therapy”), which is
commonly used to increase systemic blood pressure and car-
diac output prevent or treat post-SAH cerebral vasospasm.
Solenski et al.29 reported that pulmonary edema occurred in
29% of postoperative SAH patients in whom intentional
hypervolemia and induced hypertension were routinely em-
ployed. The lesser rate of pulmonary edema observed in
IHAST was possibly due to a lesser rate of symptomatic
vasospasm than that observed by Solenski et al. (23 vs. 46%,
respectively) and, consequently, less frequent and aggressive
hyperdynamic therapy in IHAST. Consistent with that hy-
pothesis, Kim et al.30 reported that pulmonary edema in
postoperative SAH patients decreased from 14 to 6% when
Table 4. Myocardial Injury and Dysfunction Sub-study—Left Ventricular Performance and Cardiac Troponin I
Variables
Temperature Group
P ValueHypothermia (n  33) Normothermia (n  29)
Left ventricular ejection fraction
Preoperative* 0.69 (0.64, 0.75) (n  30) 0.64 (0.62, 0.73) (n  24) 0.16
Postoperative† 0.72 (0.63, 0.75) (n  28) 0.69 (0.62, 0.73) (n  22)
Postoperative vs. preoperative
change
0.01 (0.06, 0.07) (n  26) 0.01 (0.03, 0.06) (n  20) 0.51
Regional wall motion score
Preoperative‡ 1.00 (1.00, 1.00) (n  32) 1.00 (1.00, 1.00) (n  29) 0.62
Postoperative 1.00 (1.00, 1.00) (n  33) 1.00 (1.00, 1.00) (n  29)
Postoperative vs. preoperative
change§
0.00 (0.00, 0.00) (n  32) 0.00 (0.00, 0.00) (n  29) 0.61
Cardiac troponin I (g/l)
Preoperative 0.03 (0.03, 0.04) (n  26) 0.03 (0.03, 0.03) (n  25) 0.43
Postoperative# 0.03 (0.03, 0.04) (n  26) 0.03 (0.03, 0.04) (n  24)
Postoperative vs. preoperative
change**
0.00 (0.01, 0.00) (n  26) 0.01 (0.03, 0.06) (n  24) 0.038
Values are expressed as median (25th and 75th quartile values). All P values are calculated using Wilcoxon rank sum test.
* Any preoperative left ventricular ejection fraction  50%: hypothermia  1 of 30, normothermia  0 of 24. † Any postoperative left
ventricular ejection fraction  50%: hypothermia  0 of 28, normothermia  1 of 22. ‡ Any preoperative wall motion score greater than
1.00: hypothermia  2 of 32, normothermia  1 of 29. § Any postoperative increase (worsening) of Wall Motion Score: hypothermia 
2 of 32, normothermia  2 of 29.  Any preoperative troponin  1 g/l: hypothermia  1 of 26, normothermia  0 of 25. # Any
postoperative troponin greater than 1 g/l: hypothermia  0 of 26, normothermia  2 of 24. ** Any postoperative troponin increase:
hypothermia  3 of 26, normothermia  5 of 24.
PERIOPERATIVE MEDICINE
334 Anesthesiology, V 113 • No 2 • August 2010 Nguyen et al.
less aggressive hypervolemic therapy was used. In IHAST,
postoperative congestive heart failure or pulmonary edema
was rated as mild or moderate in 80 of 94 (85%) patients.
In IHAST, the incidence of postoperative myocardial
ischemia or infarction (1%), ventricular arrhythmias (1%),
and cardiogenic shock (0%) was low and did not differ in
patients randomized to hypothermia and normothermia.
Nearly identical rates for these three events were reported
by Solenski et al.29 in a group of 455 surgical SAH pa-
tients. In IHAST, all postoperative myocardial infarctions
were nonfatal.
Perioperative Hypothermia and Cardiovascular Events
In IHAST, hypothermia was not associated with the in-
creased occurrence of any single cardiovascular event or any
composite cardiovascular event. In stark contrast, three pre-
vious studies reported that perioperative hypothermia in-
creased the incidence of cardiovascular complications.2–4
These previous studies have been cited widely and have been
used as evidence to support standards regardingmaintenance
of perioperative normothermia.††‡‡ Given the impact and
influence of previous studies and the absence of increased
cardiovascular events with perioperative hypothermia in the
IHAST population, a thorough comparison of these appar-
ently contradictory studies is warranted.
In 1993, Frank et al.2 reported a nonrandomized study of
100 patients undergoing lower extremity vascular surgery.
Patients with unintentional hypothermia (recovery room
temperatures below 35°C, n  33) had, when compared
with patients with temperatures at or above 35°C (n 67),
a greater incidence of myocardial ischemia on Holter moni-
toring (36 vs. 13%) and a greater incidence of angina (18 vs.
2%) during the first 24 h after surgery.2 There was, however,
no significant difference in the occurrence of myocardial in-
farction (4%) ormajormorbidity (12%) in hypothermic
and normothermic patients. In 1995, Bush et al.3 reported a
nonrandomized study of 262 patients undergoing abdo-
minal aortic aneurysm surgery. Patients with unintentional
hypothermia (postoperative temperatures below 34.5°C,
n  66) had, when compared with patients with tempera-
tures at or above 34.5°C (n 196), a greater need for post-
operative vasopressors (11 vs. 6%) and inotropes (35 vs.
13%) and a greater incidence of myocardial infarction (8 vs.
4%; not significant).3 Finally, in 1997, Frank et al.4 reported
a randomized trial of intraoperative temperature manage-
ment in 300 patients undergoing thoracic, abdominal, or
vascular surgery. Routine thermal management resulted in
hypothermia (35.4°C in recovery), whereas supplemental in-
traoperative warmingmaintained normothermia. Hypother-
mic patients had a greater incidence of cardiac morbidity (6
vs. 1%) and ventricular tachycardia (8 vs. 2%) during the first
24 h after surgery.4 There was, however, no significant dif-
ference in the incidence of electrocardiographic myocardial
ischemia (6%) or myocardial infarction ( 1%).
The most obvious differences between IHAST and previ-
ous reports are with regard to study design and patient char-
acteristics. In two of the three previous studies, intraoperative
and postoperative hypothermia were not intentional.2,3 In
these two studies, the development of hypothermiamay have
been the consequence of less favorable intraoperative condi-
tions. For example, in the study by Bush et al.,3 patients who
became hypothermic intraoperatively had larger aortic aneu-
rysms, greater operative time, greater fluid requirements,
greater blood loss, and greater transfusion requirements.
Some or all of these factors may have contributed to less
favorable postoperative cardiovascular outcomes rather than
hypothermia per se.
The other important difference is that the patients in
previous studies had a much greater incidence of CAD. In
the 1997 study by Frank et al.,4 49% of their patients had
known CAD compared with 5% in the IHAST population.
Frank et al. proposed that in their patients, hypothermia-
associated cardiovascular morbidity was largely the conse-
quence of increased postoperative adrenergic responses (e.g.,
hypertension and tachycardia) after emergence from anesthe-
sia. During surgery and anesthesia, Frank et al.4 observed
that the occurrence of myocardial ischemia and ventricular
arrhythmias was equivalent in hypothermic and normother-
mic patients. However, on emergence, hypothermic patients
more commonly developed hypertension, probably in response
to increased circulating catecholamines.4 This hypothesis was
based on their previous observation that hypothermic surgi-
cal patients (35.3°C in recovery) had significantly greater
postoperative plasma norepinephrine concentrations and
systemic arterial pressure than normothermic patients.9
Subsequently, Frank et al.31,32 showed in healthy volun-
teers that a 1°C decrease in core temperature increased
plasma epinephrine by 68–120%, norepinephrine by 230–
251%, rate-pressure product by 25–33%, cardiac output by
23%, and coronary blood flow by 20%. Notably, in healthy
patients, hypothermia did not change the relationship be-
tween rate-pressure product and coronary perfusion.32 In
other words, increased myocardial work and myocardial ox-
ygen requirements provoked by mild systemic hypothermia
were matched by increased coronary blood flow and did not
induce myocardial ischemia. In contrast, in patients with
flow-limiting coronary stenoses, coronary blood flow may
not be able to increase sufficiently to meet increased myocar-
dial oxygen demands triggered by hypothermia-induced ad-
renergic responses. Frank et al.32 have shown that -adren-
ergic receptor blockade decreases hypothermia-induced
†† The Joint Commission. Specifications Manual for National Hos-
pital Inpatient Quality Measures, version 3.0c, effective October 1,
2009. SCIP-Inf-10, Surgery Patients with Perioperative Temperature
Management. Available at: http://www.jointcommission.org/
PerformanceMeasurement/PerformanceMeasurement/Current
NHQMManual.htm. Accessed January 22, 2010.
‡‡ National Institute for Health and Clinical Excellence (NICE).
NICE guidance aims to prevent hypothermia in patients under-
going surgery. Available at: http://www.nice.org.uk/nicemedia/
pdf/2008029PerioperativeHypothermia.pdf. Accessed January
22, 2010.
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systemic catecholamines and eliminates hyperdynamic car-
diovascular responses.
Therefore, the collective evidence indicates that hypo-
thermia-related cardiovascular morbidity is probably due to
adrenergically mediated hemodynamic responses occurring
during or after emergence from anesthesia, which, in patients
with CAD, can increase myocardial oxygen demands to the
point of ischemia. In addition, some studies indicate that
patients with CAD may also exhibit a pathologic increase in
coronary vascular resistance in response to cold stimuli, per-
haps because of impaired coronary artery endothelial func-
tion.33,34 If so, it is possible that this response might also
contribute to hypothermia’s adverse cardiovascular effects in
patients with CAD.
Because 95% of IHAST patients had no history of CAD,
the IHAST population was at low risk of cardiovascular com-
plications on the basis of adrenergically mediated increases in
cardiac work. In the IHAST population, the incidence of
perioperative hypertension was relatively low (7%) and
was equivalent in hypothermic and normothermic patients.
Breslow et al.35 showed that general anesthesia attenuates
sympathetic activity and catecholamine responses to noxious
stimuli. By maintaining sedation or anesthesia during post-
operative rewarming, the cardiovascular effects of postoper-
ative hypothermia may have been attenuated in the small
fraction of IHAST patients who had CAD.
Accordingly, we suggest that the evidence on which peri-
operative temperature management standards are based
should be reconsidered with regard to the risks of cardiovas-
cular complications with mild perioperative hypothermia.
Maintenance of perioperative hypothermia to decrease car-
diovascular complications in patients with CADmay be rea-
sonable. Maintenance of perioperative hypothermia may be
prudent for other reasons as well, such as decreasing periop-
erative blood loss and wound infection.36 However, in pa-
tients with low risk of CAD, our findings indicate that peri-
operative hypothermia does not increase the occurrence of
cardiovascular events.
SAH-associated Myocardial Injury and Dysfunction
Multiple studies have shown that some patients with SAH
may have signs of acute myocardial injury and LV dysfunc-
tion37 and that these abnormalities may independently con-
tribute to less favorable outcomes.38,39 In a study of 182
patients with SAH, Zaroff et al.6 reported that LV regional
wall motion abnormalities were present in 25% of patients,
elevated troponin (cTnI greater than 1 g/L) was present in
13%, and decreased LVEF (less than or equal to 50%) was
present in 12%. The weight of current evidence supports the
concept that SAH-associated cardiac injury is adrenergically
mediated and triggered by pathologic release of catecholamines
at cardiac sympathetic nerve terminals at the time of the initial
SAH.8The result is awidely distributed but highly focal formof
microscopic myocardial injury referred to as contraction band
necrosis.40–46 Both clinically47 and in animal SAHmodels,42,48
contraction band necrosis is decreased by-adrenergic receptor
blockers48 and drugs that deplete norepinephrine stores.42Neil-
Dwyer et al.49 reported that patients with SAH randomized to
receive-adrenergic receptor blockers seemed to have decreased
myocardial enzyme release and improved short-term and long-
term mortality and neurologic outcome.49–51
IHAST-MIDS was an exploratory study to determine
whether perioperative hypothermia would affect the course
of SAH-associated cardiac injury and dysfunction. Unex-
pectedly, the IHAST-MIDS population differed substan-
tially from previous reports of patients with SAH6 in that it
had an extremely low incidence of preoperative myocardial
injury or dysfunction. In theMIDS population, preoperative
regional wall motion abnormalities were present in only 5%
(3 of 61 patients), increased preoperative troponin
(cTnI greater than 1 g/l) was present in 2% (1 of 51 pa-
tients), and preoperative LVEF less than 50% was present in
only 2% (1 of 54 patients). These rates were 5- to 6-fold less
than had been expected.6 The most likely explanation for the
very low incidence of SAH-associated cardiac abnormalities
in MIDS patients was their good preoperative neurologic
status; 94% (58 of 62) of patients were WFNS I or II. SAH-
associated troponin release52 and regional wall motion ab-
normalities53 are both associated with poor neurologic
grades (Hunt and Hess grades of 3 or more). Therefore, it
seems that patients who suffer the greatest degrees of neu-
rologic injury with SAH are those most likely to experi-
ence SAH-associated myocardial injury and dysfunction.
In retrospect, because the preoperative incidence of SAH-
associated myocardial injury and dysfunction was so much
less than expected, MIDS was underpowered to address the
effect of perioperative hypothermia on the pathophysiology
of SAH-associated cardiac injury. Therefore, this question
remains unanswered. Nevertheless, perioperative hypother-
mia had no sustained effect on LV function either globally or
regionally. Likewise, perioperative hypothermia was not as-
sociated with an increase in myocardial enzyme release. In
fact, the data suggest that perioperative hypothermia might
actually have had a very small beneficial effect in this regard.
This is consistent with some animal studies indicating that
mild systemic hypothermia (34°C) may decrease myocardial
infarct size.54 To date, however, human clinical trials of mild
systemic hypothermia in the setting of acute myocardial in-
farction have not consistently shown evidence of benefit.55,56
Limitations
The findings and conclusions of this study should be consid-
ered with the following limitations in mind. This report is
one of several post hoc ancillary analyses of the IHAST data-
set,28,57–62 although there is no overlap between this study
and previous IHAST post hoc analyses. A fundamental weak-
ness of any post hoc analyses is that it typically asks questions
for which the primary study was not designed. As such, post
hoc analyses should be considered a method of hypothesis
generation rather than hypothesis testing. However, IHAST
data collection was specifically designed to monitor and
compare the occurrence of predefined cardiovascular events
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in hypothermic and normothermic patients. This strength is
offset by several potential weaknesses.
One weakness is that many cardiovascular events oc-
curred at very low rates. As a result, despite a large number of
patients (1,000), the statistical power to detect a difference
between temperature groups was low for many events (e.g.,
myocardial infarction). In an attempt to address this weak-
ness, we developed several composite cardiovascular out-
come measures. None of these composite outcomes differed
between temperature groups, and in all cases, odds ratios
were very close to 1.00, indicating no increased risk with
hypothermia. For example, for “any cardiovascular event—
postoperative,” the upper confidence bound for the odds
ratio is 1.17. This means that there is a very high probability
that hypothermia increased the number of IHAST patients
who experienced postoperative cardiovascular events by no
more than 17% of the normothermic rate. With 42% of
normothermic patients experiencing a postoperative cardio-
vascular event, this means that, at most, hypothermia might
increase cardiovascular events by (17  42%) 7% (absolute
value) over that occurring with normothermia. Nevertheless,
for many other composite outcomes, the odds ratio CIs re-
mained sufficiently wide as to not preclude the possibility of
a type II error. Although we observed no indication that
perioperative hypothermia increased the incidence of cardio-
vascular events, we wish to reemphasize that this observation
must be considered to apply only to patients who have a
low-preoperative risk of CAD.
Another weakness of this post hoc analysis is that it has
limited capacity to determine the extent to which cardiovas-
cular events may have affected outcome. Although cardiovas-
cular events contributed only slightly to mortality (one pa-
tient directly and four patients indirectly), the indirect effect
of cardiovascular events on 3-month functional status is less
certain. The majority of cardiovascular events were in fact
interventions intended to support cerebral perfusion—most
commonly to prevent or treat intraoperative hypotension
and postoperative symptomatic cerebral vasospasm. Thus,
many cardiovascular events likely reflect a response to a clin-
ical event rather than being primary (causative) adverse
events. Nevertheless, it is possible that some cardiovascular
events may have had a direct effect on net neurologic recov-
ery and functional status.
Finally, although cardiovascular events were followed up
prospectively, events were detected as a part of routine clin-
ical care. Except for MIDS patients, protocol-driven serial
postoperative assessments of cardiovascular status were not
used. As a consequence, the observed rates of cardiovascular
events—in particular, postoperative myocardial infarction
and arrhythmias—are almost certainly less than if routine
serial testing been used.
Conclusion
In summary, the results of IHAST and IHAST-MIDS indi-
cate that perioperative hypothermia was not associated with
the increased occurrence of cardiovascular events in good
grade cerebral aneurysm surgery patients.
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Appendix 2. IHAST Cardiovascular Intercurrent Event Definitions
Event or Procedure Diagnostic Criteria
Hypertension, not
intended
Any instance when MAP is at or above 120 mmHg for 15 consecutive min (or longer), but
this level of hypertension was not clinically desired.
Hypertension, intended Any instance when MAP is at or above 120 mmHg for 15 consecutive min (or longer), and
this level of hypertension was clinically desired. Examples: (1) induction of hypertension
during temporary clipping; (2) induction of hypertension in an attempt to reverse new
and worse neurologic deficits.
Hypotension, not
intended
Any instance when MAP is at or below 60 mmHg for 15 consecutive min (or longer), but
this level of hypotension was not clinically desired.
Hypotension, intended Any instance when MAP is at or below 60 mmHg for 15 consecutive min (or longer), and
this level of hypotension was clinically desired. Examples: induction of hypotension
during the dissection and clipping phase of the aneurysm surgery, often referred to as
“controlled” or “induced” or “deliberate” hypotension.
Vasopressor or inotrope
administration to
support systemic
circulation*
Any instance when any vasopressor or inotropic agent is continuously administered for 15
consecutive min (or longer) to support the systemic circulation. Examples: (1)
vasopressor or inotrope administration to treat hypotension (local definition) low
systemic vascular resistance, or shock; (2) vasopressor or inotrope administration to
treat low cardiac output and cardiac or pulmonary failure.
Vasopressor or inotrope
administration to
support cerebral
circulation
Any instance when any vasopressor or inotropic agent is continuously administered for 15
consecutive min (or longer) to support the cerebral circulation. Examples: (1)
vasopressor or inotrope administration to increase MAP during temporary clipping; (2)
vasopressor or inotrope administration in an attempt to prevent or reverse new and
worse neurologic deficits.
Vasopressor or inotrope
administration for
other reasons
Any instance when any vasopressor or inotropic agent is continuously administered for 15
consecutive min (or longer) for reasons that do not fall into the two other “vasopressor
or inotrope” categories. Example: low-dose dopamine infusion for renal protection.
Myocardial ischemia or
infarction*
Any instance when there is myocardial hypoperfusion and/or myocardial cell death
mediated by inadequate coronary artery blood flow, typically associated with
atherosclerotic coronary artery disease. In the setting of acute subarachnoid
hemorrhage, electrocardiographic abnormalities which ordinarily indicate myocardial
ischemia or infarction are not, by themselves, reliable markers. Hence, the diagnosis of
myocardial ischemia and infarction in the setting of acute SAH will require, in addition to
appropriate electrocardiographic changes, at least one major, or two minor, supportive
clinical and laboratory signs. Major signs include (1) classic angina or the patient’s
anginal equivalent (with or without associated signs of nausea, diaphoresis, and anxiety);
(2) a new positive pyrophosphate scan; (3) significant stenosis of an appropriate
coronary artery (angiography); (4) autopsy confirmation of acute myocardial ischemia or
infarction. Minor signs include (1) a new and distinct increase in serum creatine kinase-
MB or troponin levels (2) associated acute hemodynamic instability; (3) associated acute
pulmonary congestion (dyspnea, orthopnea, rales, and pulmonary edema); (4) a new and
distinct regional wall motion abnormality.
Congestive heart failure
or pulmonary edema
Any instance when clinical signs and symptoms point to abnormally high left ventricular
end-diastolic pressure, resulting in translocation of fluid from the pulmonary capillaries
into the pulmonary interstitial and alveolar spaces (“hydrostatic” pulmonary edema).
Signs and symptoms include rales, increased jugular venous pressure, peripheral
edema, dyspnea at rest or on exertion, orthopnea, S3 gallop, and radiologic evidence of
pulmonary congestion (increased pulmonary vascular markings and alveolar
consolidation). Although this can occur in patients with normal ventricular function, most
often this is associated with compromised left ventricular function and diminished
cardiac reserve. Signs of low cardiac output may include relative hypotension, pallor or
cool extremities, oliguria, and low cardiac output measurements and marked wall motion
or ejection abnormalities on echocardiographic examination.
Cardiogenic shock* Any instance when there is substantively decreased cardiac output (which is not because
of hypovolemia or cardiac tamponade) associated with systemic hypoperfusion
(increased lactate concentration and oliguria) and hypotension (MAP at or below 60
mmHg). In the absence of inotropes, in cardiogenic shock, cardiac index is usually less
than 2.2 l  m2  min and mixed venous hemoglobin saturation is usually less than 65%.
(continued)
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Appendix 2. Continued
Event or Procedure Diagnostic Criteria
Supraventricular
dysrhythmia (atrial
fibrillation or atrial
flutter and other
supraventricular
tachydysrhythmia)
Any instance when a supraventricular dysrhythmia is present. Atrial fibrillation:
electrocardiogram demonstrates a lack of clearly defined P waves with an undulating
baseline that may alternate between recognizable atrial activity or nearly a flat line. The
ventricular response is irregular. Atrial flutter: electrocardiogram demonstrates “sawtooth”
atrial complexes (leads II, III, and aVF) of constant morphology, polarity, and cycle length
with a rate from 240–340 beats/min. The ventricular response rate to atrial flutter is
frequently 2:1 or 4:1 and is regular. Other supraventricular tachydysrhythmia: any form of
sustained abnormal rapid supraventricular rhythm. Examples include premature atrial
complexes, premature junctional complexes, paroxysmal atrial tachycardia, multifocal atrial
tachycardia, paroxysmal supraventricular tachycardia, atrioventricular nodal reentrant
tachycardias. It is not necessary to specify the type of abnormality.
Sinus bradycardia Any instance when the sinus node rate is equal to 40 beats/min or less.
Conduction blocks
(atrioventricular
blocks and bundle
branch blocks)
Any instance when any form of atrioventricular nodal or complete bundle branch block
exists. First-degree atrioventricular block: PR interval more than 0.2 s and each P wave
is followed by a QRS complex. Second-degree atrioventricular block: type I
(Wenckebach): progressive lengthening of the PR interval before a nonconducted P
wave; type II: constant PR interval followed by a sudden failure of a P wave to be
conducted to the ventricle. Third-degree atrioventricular block: dissociated P waves and
QRS complexes each firing at their own pacemaker rate. The atrial impulse is never
conducted to the ventricles. Bundle branch block: supraventricular rhythm with a QRS
duration  0.120 s and no Wolf-Parkinson-White pattern. Either right or left bundle
branch block qualify. Left anterior hemiblock does not qualify.
Other significant
dysrhythmia
Any other clinically significant arrhythmia that is not adequately characterized by the
arrhythmia criteria described earlier.
Ventricular fibrillation or
ventricular
tachycardia*
Any instance when either ventricular fibrillation or ventricular tachycardia is present. Ventricular
fibrillation: electrocardiogram reveals irregular and rapid oscillations (250–400 beats/min) of
highly variable amplitude without identifiable QRS complexes or T waves. With ventricular
fibrillation, there is no coordinated ventricular contraction. As a result, immediate
hemodynamic collapse always occurs. Ventricular tachycardia: any instance when there is a
series of three or more consecutive wide complex (at or above 120 ms) beats at a rate at or
above 100 beats/min, where the origin of electrical activation is the ventricle. The ventricular
complexes can be monomorphic or polymorphic (Torsades de Pointes).
Other significant
cardiovascular
disorder or
complication
Any other clinically significant cardiovascular disorder or complication that is not
adequately characterized by the criteria earlier (e.g., pericardial tamponade).
Cardioversion or
defibrillation
Any instance when electrical current is directed to the heart either directly (open chest) or
indirectly (closed chest) to treat a cardiac rhythm abnormality.
Cardiac pacemaker
placement
Any instance when any cardiac pacemaker is placed, either internal or external, regardless
of whether or not the pacemaker is, or is not, used.
Cardiopulmonary
resuscitation*
Any instance when open- or closed-chest manual cardiac compression is required.
Coronary angiogram* Any instance when any coronary angiogram is performed, regardless of specific technique.
Coronary angioplasty
and stenting*
Any instance when either coronary angioplasty is performed or an intracoronary vascular
stent is placed.
Cardiac surgery* Any instance when the patient undergoes any form of cardiac surgery. Such procedures
must occur in an operating room. This does not include angiographic procedures.
Vascular surgery Any instance when the patient undergoes any form of vascular surgery. Such procedures
must occur in an operating room.
Electrocardiogram Any instance when an electrocardiogram is performed, regardless of the reason for the
examination.
Echocardiogram Any instance when an echocardiogram is performed (transthoracic or transesophageal),
regardless of the reason for the examination.
Other cardiovascular
procedure,
intervention, or surgery
Any instance when the patient undergoes any other clinically significant cardiovascular
procedure, test, or intervention that does not fall into the above procedure categories,
(e.g., intraaortic balloon pump, pulmonary angiogram).
* “Indicator” event; see Materials and Methods for details.
MAP  mean arterial pressure; MB  muscle brain type; SAH  subarachnoid hemorrhage.
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